HHS Pandemic Influenza Vaccine Program VRBPAC Meeting Robin Robinson, Ph.D. Director, BARDA Deputy Assistant Secretary, ASPR November 14, 2012.

Slides:

Advertisements

Similar presentations

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Advertisements

Maryland 2008 Statewide Pandemic Influenza Exercise and CRA Albert Romanosky MD, PhD Office of Preparedness and Response Maryland Department of Health.

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Ready or Not? Protecting the Public’s Health from Diseases, Disasters, and Bioterrorism Jeffrey Levi, PhD Congressional Briefing February 3, 2012.

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7, 2006 By: Dr. Robin Robinson Acting Assoc. Director ORDC/OPHEP/DHHS.

Pre-2003 Pandemic Influenza Vaccine Goal & Strategy

Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,

To protect the health and environment of all Kansans by promoting responsible choices. Immunization Program 2009 H1N1 Adventure Governor’s Child Health.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Pandemic Influenza Vaccine Distribution Selected Updates Pandemic Influenza Vaccine: Doses Administered and Safety Training Conference Toscha Stanley,

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

TM Aggregate Reporting of Pandemic Influenza Vaccine Doses Administered Status and Open Q&A Joint Presentation by: Immunization Services Division National.

0 H1N1 Vaccines VRBPAC Meeting Robin Robinson, Ph.D. HHS/ASPR/BARDA Director July 23, 2009.

ASPR: Resilient People. Healthy Communities. A Nation Prepared. United States Department of Health & Human Services Office of the Assistant Secretary for.

The industry contribution to the equitable availability.

Influenza Vaccine Development

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Raymond A. Strikas, MD Associate Director for Adult Immunization Immunization Services Division National Immunization Program Coordinating Center for Infectious.

U.S. Pandemic Preparedness Medical Countermeasures Program: Development, Stockpiling, & Infrastructure Building National Emergency Management Summit Washington,

Medical Surge Capacity Planning: A National Perspective Jeanne S. Ringel, PhD June 8, 2008.

Immunization in the Time of H1N1 Anne Schuchat, MD Rear Admiral, US Public Health Service Director, National Center for Immunization and Respiratory Diseases.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Shelf Life Extension Program (SLEP)

HHS Pandemic Influenza Preparedness Planning Julie Louise Gerberding, MD, MPH.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Office of Public Health Preparedness and Response Division of Strategic National Stockpile Ben Erickson Public Health Analyst Inventory Management Tracking,

Food and Drug Administration

U.S. Pandemic Influenza Preparedness and Response: Update & Progress Report “The pandemic influenza clock is ticking. We just don’t know what time it is.”

A Potential Influenza Pandemic: Possible Macroeconomic Effects and Policy Issues Julie Somers Congressional Budget Office Prepared for the Ninth Annual.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

America Responds: An HHS 2009-H1N1 Retrospective to Advance All Hazards Preparedness Discussion with the National Vaccine Advisory Committee June 3, 2010.

Global Pandemic Preparedness Research Efforts text Klaus Stöhr WHO Global Influenza Programme 3 Today  Medium-term applied research linked to medical.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

Ready or Not? Protecting the Public’s Health from Diseases, Disasters, and Bioterrorism Jeff Levi, PhD Executive Director Trust for America’s Health.

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

The Integrated National Biodefense Portfolio Initiative “One-Portfolio” Chemical Biological Defense Acquisition Initiatives Forum (CBDAIF) May 6, 2009.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY.

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

An Overview of Pandemic Influenza Planning in the United States NAPHSIS Annual Meeting June 7, 2006 David K. Shay Influenza.

TM 1 Tracking Novel Influenza A H1N1 Vaccine Doses Administered May 13, 2009 Presentation by Division of Emergency Preparedness and Response National Center.

NVAC Influenza Working Group Vaccine Research, Development and Production.

Planning for the Influenza Season National Vaccine Advisory Committee February 8, 2005 Washington, DC Lance E. Rodewald, MD Director, Immunization.

1 NVAC Washington, D.C. February 3, Agenda I.Overview of Influenza Vaccine Production and Development II.Vaccine Supply/Demand: Recent Trends.

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

Update from the 2010 National Influenza Vaccine Summit meeting L.J Tan Co-chair, National Influenza Vaccine Summit Director, Medicine and Public Health,

Implementation of the Pandemic and All-Hazards Preparedness Act Briefing for National Vaccine Advisory Commitee February 5, 2007 By: Brian Kamoie Acting.

HHS Smallpox Vaccine Program & ACAM2000 Briefing for VRBPAC 17 May 2007 Dr. Gerald Parker Principal Deputy Assistant Secretary for Preparedness and Response.

1 H5N1 Influenza Virus Vaccine, A/Vietnam/1203/2004 (Clade 1) VRBPAC Presentation Kenneth P. Guito, MBA Strategic Project Office.

Pandemic Influenza: Planning and Preparedness Ben Schwartz, M.D. National Vaccine Program Office, U.S. Department of Health and Human Services NVAC Meeting,

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

GLOBAL HEALTH SECURITY text Looking Ahead: Strategies for Building a Platform Pandemic Influenza Vaccines: Building a Platform for Global Collaboration.

COOP Continuity of Operations. COOP COOP is “Good Business Practice” Ensure that county and state agencies can maintain and continue operations Ensure.

The National Vaccine Plan Update: Recent Activities and Next Steps Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

Partnerships for Pandemic & Bioterrorism Incidents

Luke Bowen – Exercise Facilitator

Overview of Pandemic Influenza Planning Guide for SLTT

Moving Forward From Fukushima Near-Term Task Force EP Recommendations

Broader Horizons for Immunization:

Presentation transcript:

HHS Pandemic Influenza Vaccine Program VRBPAC Meeting Robin Robinson, Ph.D. Director, BARDA Deputy Assistant Secretary, ASPR November 14, 2012

U.S. Pandemic Influenza Plans Laid the Pathway for Pandemic Vaccines

2 Vaccine Strategic Goals Were Specific on Expectations Goal #1: Establish & maintain dynamic pre- pandemic influenza vaccine stockpiles available for 20 M persons (2 doses/person): H5N1 stockpiles Goal #2: Provide pandemic vaccine to all U.S. citizens within 6 months of a pandemic declaration: pandemic vaccine (600 M doses) National Strategy for Pandemic Influenza (Nov 2005) and HHS Pandemic Influenza Plan (Nov 2005)

3 Seasonal Influenza Preparednes s Pandemic Influenza Preparedness for other hazards Vaccine Development, Planning, & Infrastructure Must Address Both Seasonal and Pandemic Influenza Unifying Principle

Pandemic Influenza Vaccine Implementation Goals Fortify existing influenza vaccine capabilities Support development of better influenza vaccines that afford greater surge manufacturing capacity ─Cell-based Vaccines ─Recombinant and Molecular Vaccines ─Adjuvants for Dose- and Antigen-sparing ─Universal Influenza Vaccines Establish pre-pandemic influenza vaccine stockpile Expand domestic manufacturing capacity ─Retrofit existing facilities ─Establish new facilities

5 National Pandemic Influenza Vaccine Development Strategy Is Multi-Step & Integrated Approach Cell-based Vaccines Egg-based Vaccines Recombinant- based Vaccines Universal Vaccines Antigen-Sparing Vaccine Technology “More and better vaccines sooner”

Pandemic Influenza Scenario Relied on Existing Capabilities Antigen-Alone Egg-based Vaccines Pan Flu Illnesses weeks Unabated Pandemic Wave Idealized Pandemic Wave

7 New Vaccines & Domestic Facilities Will Help Close the U.S. Pan Flu Vaccine Gap this Decade Egg- & Cell- based Vaccines with Adjuvants Recombinant Vaccines with Adjuvants Pre-pandemic Vaccines weeks weeks Pan Flu Illnesses

8 Universal Flu Vaccines Will Transform Seasonal & Pandemic Influenza Preparedness Egg- & Cell- based Vaccines with Adjuvants Recombinant Vaccines with Adjuvants Universal Vaccines weeks weeks “Priming Dose” “Booster Dose” Pan Flu Illnesses

HHS Has Supported Development of Multiple Antigen-sparing Flu Vaccine Adjuvant Technologies Supported multiple projects in (H5N1) & in 2009 (H1N1) for advanced development of pandemic influenza vaccines with adjuvants towards US-licensure Vaccine candidates are at various stages of development with Q-Pan representing one mature vaccine candidate Multiple study results (academia, USG, & vax mfg.) have shown that different oil-in-water emulsion adjuvants confer additional properties onto flu vaccines ─antigen- & dose-sparing effects ─cross-strain protection ─prolonged prime-boost immunity Mix-N-Match studies showed that H1 and H5 vaccine antigens from one manufacturer combined with adjuvants from other manufacturers are immunogenic

HHS Has Established H5N1 Vaccine Stockpile Available for Deployment HHS/BARDA established & manages H5N1 vaccine antigen (4 strains) and adjuvant (2) stockpiles stored and routinely tested at domestic vaccine manufacturing sites U.S. pan flu preparedness stockpiling goal met in 2008 Stockpile needs evaluated annually using CDC’S Influenza Risk Assessment Tool (e.g., H3N2v – 2012) Potency of bulk vaccine antigen lots remains >75% after 5-8 years & bulk adjuvant lots near 100% after 4-5 years Pre-EUA packages submitted by BARDA in 2012 to FDA for stockpiled vaccines with adjuvants Vaccine distribution through central distribution system managed by CDC

Licensure of H5N1 Vaccine with Adjuvant Caps Development & Initiates Further Partnering Milestone achievement for U.S. pandemic preparedness realized with licensure of H5N1 vaccine with adjuvant USG (CDC, FDA, BARDA, DoD, & others) and flu vaccine manufacturers will continue partnering on post-licensure activities for seasonal and H5N1 flu vaccines. ─seasonal flu vaccine safety & performance tracking ─planning future U.S. tracking systems for influenza vaccine safety and effectiveness ─executing these tracking systems during inter-pandemic periods and influenza pandemics